-
-
-
-
-
-
-
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
-
-
-
-
-
-
-
Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020
-
-
-
-
-
-
-
FDA Advisory Committee Sets Review Date for Mesoblast’s remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host Disease
-
-
-
15,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

